Open Access Open Badges Research article

Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Hakan Leblebicioglu1*, Nedim Cakir2, Mustafa Celen3, Halil Kurt4, Hakan Baris5, Joerg Laeuffer6 and Turkish COMPACT Study Group

Author Affiliations

1 Ondokuzmayis University, Kurupelit Kampüsü, PK 55139, Kurupelit, Samsun, Turkey

2 Dokuz Eylül University Infectious Disease Clinic, 35340, İnciralti İZMİR, Izmir, Turkey

3 Dicle University Infectious Disease Clinic, 21280, Diyarbakir, Turkey

4 Ankara University Infectious Disease Clinic, PK 06230, Altindağ, Gündoğdu Ankara, Turkey

5 Janssen-Turkey, Ertürk Sok, Keçeli Plaza No: 13 34810, Kavacik, Beykoz, Istanbul, Turkey

6 Janssen-EMEA, Sihlbruggstrasse 111, 6340, Baar, Switzerland

For all author emails, please log on.

BMC Infectious Diseases 2012, 12:42  doi:10.1186/1471-2334-12-42

Published: 16 February 2012



Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are Pseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired infections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics against Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT) study centres in Turkey.


Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other Gram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections, bloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and October 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species confirmation as well as limited susceptibility and quality-control testing.


Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and imipenem, respectively, were 32, ≥ 64, and ≥ 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against Enterobacteriaceae; and ≥ 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility of hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found that against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.


Doripenem showed similar or slightly better activity than meropenem and better activity than imipenem against the Gram-negative pathogens collected in Turkey.